Clinical Trials
A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan (AC): A Validation
Biomarkers (traits of the genes inside cancer cells) may help us predict how well individual breast cancers respond to chemotherapy drugs (Taxotere and Adriamycin/Cytoxan).
- Patient Population:
- Primary breast cancer must be of clinical and/or radiologic size >3 cm and deemed surgically operable.
- All patients will receive one of the following:
- Taxotere for 4 treatments, then surgery, followed by Adriamycin and Cytoxan (AC) for 4 treatments; or
- AC for 4 treatments, then surgery, followed by Taxotere for 4 treatments.
Biopsies may be performed prior to beginning chemotherapy and immediately before the second treatment. Tissue will also be obtained at the time of surgery.
For more information or to have a patient screened, contact the Taxotere and AC Validation Study Coordinator at 713-798-1986.